130 related articles for article (PubMed ID: 32861994)
1. Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy.
Huang S; Zhou N; Zhao L; Gimple RC; Ahn YH; Zhang P; Wang W; Shao B; Yang J; Zhang Q; Zhao S; Jiang X; Chen Z; Zeng Y; Hu H; Gustafsson JÅ; Zhou S
iScience; 2020 Sep; 23(9):101458. PubMed ID: 32861994
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor beta signaling in CD8
Yuan B; Clark CA; Wu B; Yang J; Drerup JM; Li T; Jin VX; Hu Y; Curiel TJ; Li R
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462142
[TBL] [Abstract][Full Text] [Related]
3. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
4. A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.
Jeon Y; Kang H; Yang Y; Park D; Choi B; Kim J; Kim J; Nam K
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230744
[TBL] [Abstract][Full Text] [Related]
5. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Zhao L; Huang S; Mei S; Yang Z; Xu L; Zhou N; Yang Q; Shen Q; Wang W; Le X; Lau WB; Lau B; Wang X; Yi T; Zhao X; Wei Y; Warner M; Gustafsson JÅ; Zhou S
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3673-E3681. PubMed ID: 29592953
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
10. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
11. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
12. Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade.
Alexander ET; Mariner K; Donnelly J; Phanstiel O; Gilmour SK
Mol Cancer Ther; 2020 Oct; 19(10):2012-2022. PubMed ID: 32747421
[TBL] [Abstract][Full Text] [Related]
13. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid-derived suppressor cells for cancer therapy.
Tang H; Li H; Sun Z
Cancer Biol Med; 2021 Aug; 18(4):992-1009. PubMed ID: 34403220
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
16. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
[TBL] [Abstract][Full Text] [Related]
17. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
18. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
[TBL] [Abstract][Full Text] [Related]
19. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
